Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Intangibles: 2016-2025

Historic Intangibles for Ironwood Pharmaceuticals (IRWD) over the last 5 years, with Sep 2025 value amounting to $2.2 million.

  • Ironwood Pharmaceuticals' Intangibles fell 26.74% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 26.74%. This contributed to the annual value of $2.9 million for FY2024, which is 22.32% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Intangibles is $2.2 million, which was down 8.40% from $2.5 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Intangibles high stood at $4.1 million for Q2 2023, and its period low was $2.2 million during Q3 2025.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Intangibles value was $3.2 million (recorded in 2024), while the average stood at $3.2 million.
  • Data for Ironwood Pharmaceuticals' Intangibles shows a maximum YoY dropped of 26.74% (in 2025) over the last 5 years.
  • Ironwood Pharmaceuticals' Intangibles (Quarterly) stood at $3.7 million in 2023, then dropped by 22.32% to $2.9 million in 2024, then dropped by 26.74% to $2.2 million in 2025.
  • Its Intangibles was $2.2 million in Q3 2025, compared to $2.5 million in Q2 2025 and $2.7 million in Q1 2025.